Overall, the combination of CD137, TNF, and IFNγ via intracellular detection was feasible and the use of CD137 improved the detection of tumor-specific reactive CD8+ TILs by more than 20% compared to the combination of TNF, IFNγ; and CD107a. The gene discussed is CD8A; the disease is neoplasm.